Ajulemic acid (AJA, CT-3, IP-751, JBT-101, anabasum) is a first-in-class, synthetic, orally active, cannabinoid-derived drug that preferentially binds to the CB2 receptor and is nonpsychoactive. In preclinical studies, and in Phase 1 and 2 clinical trials, AJA showed a favorable safety, tolerability, and pharmacokinetic profile. It also demonstrated significant efficacy in preclinical models of inflammation and fibrosis. It suppresses tissue scarring and stimulates endogenous eicosanoids that resolve chronic inflammation and fibrosis without causing immunosuppression. AJA is currently being developed for use in 4 separate but related indications including systemic sclerosis (SSc), cystic fibrosis, dermatomyositis (DM), and systemic lupus erythematosus. Phase 2 clinical trials in the first 3 targets demonstrated that it is safe, is a potential treatment for these orphan diseases and appears to be a potent inflammation-resolving drug with a unique mechanism of action, distinct from the nonsteroidal anti-inflammatory drug (NSAID), and will be useful for treating a wide range of chronic inflammatory diseases. It may be considered to be a disease-modifying drug unlike most NSAIDs that only provide symptomatic relief. AJA is currently being evaluated in 24-month open-label extension studies in SSc and in skin-predominant DM.
several of its potentially important preclinical actions are now reviewed in some detail.
| BACKGROUND AND HISTORY
The preclinical literature on AJA has been briefly reviewed, 2 however, in this presentation, several selected, as well as newly reported areas, are discussed in more detail. These have been chosen because they suggest therapeutic targets where AJA may be efficacious in the treatment of human disease. Specifically, they are arthritis, fibrosis and metastatic disease. Each of the 3 represent a major under met medical need.
| Rheumatoid arthritis
Joint tissue injury in patients with rheumatoid arthritis (RA) is due in part to activation of T lymphocytes in the synovia; T lymphocytes in synovia of RA patients are resistant to apoptosis.
Oral administration of AJA prevents joint cartilage and bone damage in an experimental model of arthritis in rats. 3 Thus, a potential mechanism whereby AJA prevents joint tissue injury in this animal model might be an enhanced apoptosis of T lymphocytes. Apoptosis of human T cells in vitro was assessed by annexin V expression, caspase-3 activity, DNA fragmentation, and microscopy. 4, 5 AJA induced apoptosis of T cells in a dose-and time-dependent manner. Apoptosis preceded loss of cell viability by trypan blue dye exclusion, confirming that cell loss was due to programmed death rather than necrosis. This suggests that a nontoxic compound such as AJA may be a useful therapeutic agent for patients with diseases such as RA that are characterized by T-cell-driven chronic inflammation and tissue injury. seems likely that AJA may be a useful drug for diseases such as RA and osteoporosis in which bone resorption is a central feature.
| Multiple sclerosis
In multiple sclerosis (MS), damage to myelin in the central nervous sys- identified as a substance that is able to reduce MS-induced spasticity presumably by its inflammation resolving action on peripheral nerves. 6 
| Antifibrotic effects
Bleomycin (BLM)-induced experimental fibrosis in mice was used to assess the antifibrotic effects of AJA in vivo. 7, 8 Initially, acute inflammation characterized by neutrophil and macrophage accumulation were the main changes present in lung parenchyma. 8 Between 8 and 14 days after BLM administration, the response progresses from inflammation to fibrosis and involves the bronchi and vasculature.
The fibrotic response in lung tissue at day 21 after BLM treatment was significantly reduced in mice receiving either AJA in the inflammatory or in the early fibrogenic phase. A marked change in the expression pattern of substances implicated in fibrogenesis, such as TGF-b1, pSMAD2/3, CTGF, and a-SMA was observed.
| Cancer and antimetastatic effects
Early observations on inhibition of cell proliferation by AJA (Burstein SH and Zurier RB, unpublished) prompted a study of its possible anticancer actions. 9 AJA was compared with THC as an antineoplastic agent and was found to be nearly equipotent in vitro and more 12 An example of such a mechanism comes from a randomized, double-blind, placebo-controlled trial of the IL-1b inhibitor, canakinumab. 13 Thus, it is quite reasonable to suggest that IL1b inhibitors, such as AJA, could produce a similar therapeutic action without side effects. mice. This may be partly due to the anti-inflammatory properties of AJA and to its effect on several matrix metalloproteinases. 14 Also, the appearance of the primary tumors was different in the drug-treated mice vs. the vehicle-treated mice. The AJA-treated mice had discrete well-defined tumors, whereas the vehicle-treated control mice pro- CFTR-deficient mice. 16 In the first series of studies, wild-type (WT) C57BL/6J animals were utilized to evaluate oral dosing, safety and toxicity of AJA. In the second series of studies, a limited number of both WT and CF mice were evaluated for safety, toxicity, and efficacy upon oral dosing AJA. As controls, PA infected WT and CF mice were given the vehicle. The mice were followed daily for clinical score and weights for 10 days. At day 10, animals were eutha- found in the rat hepatocyte incubations. Unchanged amounts of AJA detected after the 2-hour incubations were 103%, 90%, 86%, and 83% for rat, dog, monkey, and human hepatocytes, respectively.
| Lack of effects on cytochrome metabolism of other molecules
Additional studies were done to ascertain if AJA inhibits the activities of 5 of the principal human cytochrome P450 isozymes; (cytochrome P450 isoform 1A2, cytochrome P450 isoform 2C9, cytochrome P450 isoform 2C19, cytochrome P450 isoform 2D6, and cytochrome P450 isoform 3A4/5) CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5 involved in drug metabolism. In contrast to the phytocannabinoids, THC and CBD, that can inhibit these enzymes, with AJA, no significant inhibition of cytochrome activity was observed. These data further support the conclusion reached in earlier reports on AJA's high margin of safety and indicates that it undergoes minimal metabolism and is not likely to interfere with the normal metabolism of drugs or endogenous substances.
| CLINICAL TRIALS

| Pharmacokinetics
As part of a Phase 1 safety trial, the pharmacokinetics of single oral doses of 0-10 mg of AJA was carried out (Atlantic Pharmaceuticals, unpublished data). A group of 32 healthy adult male subjects was monitored by mass spectrometric methods for 24 hours after dosing.
The data showed that AJA was rapidly absorbed and is eliminated with a half-life of about 3 hours. A linear relationship of the area under the curve (AUC) and C max over the 1-10 mg dose range was observed. It can also affect blood vessels, muscles, and joints. The tissues of involved organs become hard and fibrous, causing them to function less efficiently. Inflammation is thought to be the driving force behind the disease, leading to increased fibrosis and ultimate mortality.
Regarding molecular events, the proinflammatory and profibrotic cytokine TGF-b has been identified as an important mediator.
A multicenter, double-blinded, randomized, placebo-controlled Recently a Phase 2, double-blinded, randomized, placebo-controlled multicenter study to evaluate safety, tolerability, and pharmacokinetics of AJA in CF was completed (ClinicalTrials.gov Identifier: NCT02465450) and the topline results have been reported. 18, 5, 6 This trial tested the safety, tolerability, and pharmacokinetics (PK) of AJA in 85 subjects between 18 and 65 years of age with documented
CF. An earlier trial in healthy humans measured PK values and is dis- 
| Dermatomyositis
Dermatomyositis (DM) is a connective tissue disease that is characterized by inflammation of the muscles and the skin. It is a systemic disorder that may also affect the joints, the esophagus, the lungs, and the heart. In the United States, the incidence of DM is estimated at 5.5 cases per million people.
An in vitro study using peripheral blood mononuclear cells (PBMCs) from dermatomyositis patients showed that AJA treatment 
| SAFE TY AND TOLERABILITY
| Lack of ulcerogenicity
The most significant unwanted side effect of many anti-inflammatory agents is the formation of gastrointestinal ulcers. For this reason, AJA was carefully examined to detect any possible ulcerogenicity. When given acutely to rats in doses up to 1000 mg/kg, no evidence for ulcer formation was seen. Chronic intragastric administration of up to 30 mg/kg likewise resulted in no ulcerogenicity, whereas the positive control indomethacin-treated rats showed extensive ulcer formation. 23 AJA has a very favorable therapeutic index for ulcerogenicity vs inflammation when compared to several NSAIDs (Table 1) .
| Toxicity
Because of its structural similarity to THC, AJA was studied for possible induction of opiate like physical dependence in a 14-day rat study. 24 None of the typical opiate withdrawal effects such as writhing, diarrhea, wet dog shakes, etc., were observed indicating that AJA has a low dependence liability. There were no effects on renal, cardiovascular, or gastrointestinal function, and no signs of respiratory depression as well. Lethal doses were estimated following single doses in mice (600 mg/kg) and in rats (400 mg/kg). AJA was well tolerated at doses up to 50 mg/kg. Three different standard tests for mutagenic potential gave negative findings.
| MECHAN ISM OF ACTION
| Cannabinoid receptors
In recent years, the discovery of CB2-specific agonists has been an important goal in the area of therapeutics. CB2 is a member of the G-protein-coupled receptor (GPCR) superfamily and its pharmacology has been reviewed in some detail. 25 CB2 receptors are primarily expressed in the periphery, including cells involved in immune system activities. Although CB2 has been detected in the CNS, its actions do not include mood alteration or behavioral responses.
Receptor binding studies using highly purified preparations of AJA showed~12-fold selectivity for CB2 over CB1 receptors, whereas preparations described in previous reports showed much higher activity at CB1 relative to CB2 ( Table 2 ). The highly purified preparation of AJA stimulated release of PGJ in a CB2-dependent manner and produced minimal catalepsy or hypothermia, effects primarily mediated by CB1 receptors. 2 In contrast, AJA preparations described in earlier reports had higher CB1 binding activity and caused concomitantly greater catalepsy and hypothermia, 
| Drug distribution
The structure of AJA suggests an inability to cross the blood-brain barrier in humans due to its polarity and molecular weight. Evidence from distribution studies in rats is in agreement with this possibility. 26 Therefore, in addition to its selectivity for CB2 over CB1, the poor brain uptake of AJA will further favor its actions toward activating CB2 receptors on immune cells in the periphery, as opposed to stimulating CB1 receptors in the CNS. 
| Preclinical mechanism studies
The major precursor for all of the eicosanoids is free arachidonic acid (AA) whose release from phospholipid storage sites is robustly stimulated by AJA ( Figure 3) . 27 This initiates a cascade of events leading to the eicosanoid superfamily, one branch of which is shown in Fig The ability of AJA to increase the production of the proresolving eicosanoid PGJ has been confirmed experimentally; application of AJA to HL60 cells produced a robust stimulation of PGJ. 27 The AJAinduced increase in PGJ was effectively inhibited by the CB2 antagonist SR144528 (1 lmol/L), whereas the CB1 antagonist SR141716 (10 lmol/L) had only a small effect, suggesting a CB2 receptor-mediated mechanism of action. 1, 27 A second eicosanoid, lipoxin A 4 (LXA 4 ), has also been reported to contribute to the inflammation resolving action of AJA. 29 In Organ fibrosis can be an ultimate result of unresolved chronic inflammation.
| Mechanism studies in humans
To further explore its mechanism of action, and establish a pharma- 
| SUMMARY AND CONCLUSION S
Thus far, the available preclinical (Table 3 ) and clinical data (Table 4) suggest that AJA could provide a safe and effective treatment for diseases that are characterized by chronic inflammation and eventually result in fibrosis, loss of function, etc. Data from in vitro experiments suggest that the CB2 receptor is an important mediator and that AJA can act as an inflammation-resolving agent through its stimulatory action on the production of the proresolving agents PGJ and LXA 4 . Its ability to lower IL-1b inhibitor a factor in some of its actions. Based on its structural overlap with AA, it has been suggested that AJA should be referred to as an arachidomimetic agent. 
